Journal Description
Current Oncology
Current Oncology
is an international, peer-reviewed, open access journal published online by MDPI (from Volume 28 Issue 1-2021). Established in 1994, the journal represents a multidisciplinary medium for clinical oncologists to report and review progress in the management of this disease. The Canadian Association of Medical Oncologists (CAMO), the Canadian Association of Psychosocial Oncology (CAPO), the Canadian Association of General Practitioners in Oncology (CAGPO), the Cell Therapy Transplant Canada (CTTC), the Canadian Leukemia Study Group (CLSG) and others are affiliated with the journal and their members receive a discount on the article processing charges.
- Open Access— free for readers, with article processing charges (APC) paid by authors or their institutions.
- High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.
- Journal Rank: JCR - Q2 (Oncology)
- Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2024).
- Recognition of Reviewers: APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.
Impact Factor:
2.8 (2023);
5-Year Impact Factor:
2.9 (2023)
Latest Articles
Risk Factors for Postoperative Nausea and Vomiting After TACE: A Prospective Cohort Study
Curr. Oncol. 2025, 32(1), 17; https://doi.org/10.3390/curroncol32010017 (registering DOI) - 28 Dec 2024
Abstract
Abstract: Objective: Postoperative nausea and vomiting (PONV) was one of the common complications in patients with HCC who had undergone TACE. This study was a prospective analysis of patient data to investigate risk factors for PONV in patients after TACE. Material and Methods:
[...] Read more.
Abstract: Objective: Postoperative nausea and vomiting (PONV) was one of the common complications in patients with HCC who had undergone TACE. This study was a prospective analysis of patient data to investigate risk factors for PONV in patients after TACE. Material and Methods: Data were collected from 212 patients undergoing TACE in the interventional department between August 2022 and August 2023. Including: gender, age, education, BMI, operation time, concomitant underlying diseases and drugs, preoperative limosis, history of nausea and vomiting, history of kinetosis, history of smoking or drinking, and occurrence of PONV. A visual analog scale was used to measured pain. Neuropsychological status was also assessed, using the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7) and the Patient Health Questionnaire-9(PHQ-9). To identify risk factors for PONV, multiple logistic regression analysis was used. The receiver operating characteristic (ROC) curve was plotted to assess the regression model. The clinical trial number did not apply in the study. Results: In this study, 212 out of a total of 904 patients with HCC undergoing TACE during their hospital stay were included for analysis. Among the included patients, the incidence of PONV was as high as 42% (89/212). Multiple logistic regression analysis showed that chronic gastritis (odds ratio [OR] = 10.350; p = 0.020), VAS (OR = 3.835; p = 0.003), epirubicin (OR = 26.685; p < 0.001), and the dosage of lipiodol (≥5 mL) (OR = 1.385; p < 0.001) were independent risk factors of PONV after TACE. The ROC curve demonstrated that the AUC was 0.902, the sensitivity was 84.3%, and the specificity was 87%. Conclusions: PONV is highly prevalent among patients with HCC after TACE. Chronic gastritis, pain, epirubicin, and the dosage of lipiodol were independent risk factors for PONV. The risk prediction model that was constructed according to the aforementioned factors demonstrated good discriminatory capacity for predicting the risk of post-TACE PONV, which can improve the recognition of medical providers, and has a good ability to prevent and treat nausea and vomiting.
Full article
Open AccessReview
Understanding the Immune System and Biospecimen-Based Response in Glioblastoma: A Practical Guide to Utilizing Signal Redundancy for Biomarker and Immune Signature Discovery
by
Luke R. Jackson, Anna Erickson, Kevin Camphausen and Andra V. Krauze
Curr. Oncol. 2025, 32(1), 16; https://doi.org/10.3390/curroncol32010016 (registering DOI) - 28 Dec 2024
Abstract
Glioblastoma (GBM) is a primary central nervous system malignancy with a median survival of 15–20 months. The presence of both intra- and intertumoral heterogeneity limits understanding of biological mechanisms leading to tumor resistance, including immune escape. An attractive field of research to examine
[...] Read more.
Glioblastoma (GBM) is a primary central nervous system malignancy with a median survival of 15–20 months. The presence of both intra- and intertumoral heterogeneity limits understanding of biological mechanisms leading to tumor resistance, including immune escape. An attractive field of research to examine treatment resistance are immune signatures composed of cluster of differentiation (CD) markers and cytokines. CD markers are surface markers expressed on various cells throughout the body, often associated with immune cells. Cytokines are the effector molecules of the immune system. Together, CD markers and cytokines can serve as useful biomarkers to reflect immune status in patients with GBM. However, there are gaps in the understanding of the intricate interactions between GBM and the peripheral immune system and how these interactions change with standard and immune-modulating treatments. The key to understanding the true nature of these interactions is through multi-omic analysis of tumor progression and treatment response. This review aims to identify potential non-invasive blood-based biomarkers that can contribute to an immune signature through multi-omic approaches, leading to a better understanding of immune involvement in GBM.
Full article
(This article belongs to the Special Issue The 30th Anniversary of Current Oncology: Perspectives in Clinical Oncology Practice)
►▼
Show Figures
Figure 1
Figure 1
Open AccessReview
Focal Therapy for Prostate Cancer: Recent Advances and Insights
by
Francesco Lasorsa, Arianna Biasatti, Angelo Orsini, Gabriele Bignante, Gabriana M. Farah, Savio Domenico Pandolfo, Luca Lambertini, Deepika Reddy, Rocco Damiano, Pasquale Ditonno, Giuseppe Lucarelli, Riccardo Autorino and Srinivas Vourganti
Curr. Oncol. 2025, 32(1), 15; https://doi.org/10.3390/curroncol32010015 (registering DOI) - 28 Dec 2024
Abstract
Focal therapy has emerged as a balanced middle ground aiming to reduce overtreatment and the risk of progression, as well as patients’ distress and anxiety. Focal therapy and partial gland ablation prioritize the precise elimination of the index lesion and a surrounding safety
[...] Read more.
Focal therapy has emerged as a balanced middle ground aiming to reduce overtreatment and the risk of progression, as well as patients’ distress and anxiety. Focal therapy and partial gland ablation prioritize the precise elimination of the index lesion and a surrounding safety margin to optimize treatment outcomes and lower the risk of residual disease. The paradigm of whole-gland ablation has shifted towards more targeted approaches. Several treatment templates ranging from subtotal and hemiablation to “hockey-stick”, quadrant, and even focal lesion ablation have emerged. Many types of energy may be utilized during focal treatment. First, focal therapy can be grossly classified into thermal vs. non-thermal energy. The aim of this non-systematic review is to offer a comprehensive analysis of recently available evidence on focal therapy for PCa.
Full article
(This article belongs to the Special Issue Innovations in Combining SBRT and Systemic Treatments for Urological Cancers)
►▼
Show Figures
Figure 1
Open AccessCommentary
Building a Genomics-Informed Nursing Workforce: Recommendations for Oncology Nursing Practice and Beyond
by
Jacqueline Limoges, Rebecca Puddester, Andrea Gretchev, Patrick Chiu, Kathy Calzone, Kathleen Leslie, April Pike and Nicole Letourneau
Curr. Oncol. 2025, 32(1), 14; https://doi.org/10.3390/curroncol32010014 (registering DOI) - 27 Dec 2024
Abstract
Background: Genomics is a foundational element of precision health and can be used to identify inherited cancers, cancer related risks, therapeutic decisions, and to address health disparities. However, there are structural barriers across the cancer care continuum, including an underprepared nursing workforce, long
[...] Read more.
Background: Genomics is a foundational element of precision health and can be used to identify inherited cancers, cancer related risks, therapeutic decisions, and to address health disparities. However, there are structural barriers across the cancer care continuum, including an underprepared nursing workforce, long wait times for service, and inadequate policy infrastructure that limit equitable access to the benefits of genomic discoveries. These barriers have persisted for decades, yet they are modifiable. Two distinct waves of efforts to integrate genomics into nursing practice are analyzed. Drawing on research and observations during these waves, this discussion paper explores additional approaches to accelerate workforce development and health system transformation. Results: Three recommendations for a third wave of efforts to integrate genomics are explored. (1) Collaborate across the domains of nursing practice, professions, and sectors to reset priorities in response to emerging evidence, (2) Education in leadership, policy and practice for rapid scale-up of workforce and health system transformation, and (3) Create a research framework that generates evidence to guide nursing practice. Conclusions: Preparing nurses to lead and practice at the forefront of innovation requires concerted efforts by nurses in all five domains of practice and can optimize health outcomes. Leveraging nursing as a global profession with new strategies can advance genomics-informed nursing.
Full article
(This article belongs to the Special Issue Feature Reviews in Section "Oncology Nursing")
Open AccessArticle
Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada
by
Lara Chayab, Natasha B. Leighl, Mina Tadrous, Christine M. Warren and William W. L. Wong
Curr. Oncol. 2025, 32(1), 13; https://doi.org/10.3390/curroncol32010013 - 27 Dec 2024
Abstract
The treatment landscape for patients with advanced ALK-positive NSCLC has rapidly evolved following the approval of several ALK TKIs in Canada. However, public funding of ALK TKIs is mostly limited to the first line treatment setting. Using linked provincial health administrative databases, we
[...] Read more.
The treatment landscape for patients with advanced ALK-positive NSCLC has rapidly evolved following the approval of several ALK TKIs in Canada. However, public funding of ALK TKIs is mostly limited to the first line treatment setting. Using linked provincial health administrative databases, we examined real-world outcomes of patients with advanced ALK-positive NSCLC receiving ALK TKIs in Ontario between 1 January 2012 and 31 December 2021. Demographic, clinical characteristics and treatment patterns were summarized using descriptive statistics. Kaplan–Meier analysis was performed to evaluate progression-free survival (PFS) and overall survival (OS) among the treatment groups. A total of 413 patients were identified. Patients were administered alectinib (n = 154), crizotinib (n = 80), or palliative-intent chemotherapy (n = 55) in the first-line treatment. There was a significant difference in first-line PFS between the treatment groups. The median PFS (mPFS) was not reached for alectinib (95% CI, 568 days—not reached), compared to 8.2 months (95% CI, 171–294 days) for crizotinib (HR = 0.34, p < 0.0001) and 2.4 months (95% CI, 65–100 days) for chemotherapy (HR = 0.14, p < 0.0001). There was no significant difference in first-line OS between the treatment groups. In patients who received more than one line of treatment, there was a significant difference in mOS between patients who received two or more lines of ALK TKIs compared to those who received one line of ALK TKI (mOS = 55 months (95% CI, 400–987 days) and 26 months (95% CI, 1448–2644 days), respectively, HR = 4.64, p < 0.0001). This study confirms the effectiveness of ALK TKIs in real-world practice and supports the potential benefit of multiple lines of ALK TKI on overall survival in patients with ALK-positive NSCLC.
Full article
(This article belongs to the Section Thoracic Oncology)
►▼
Show Figures
Figure 1
Figure 1
Open AccessArticle
Open Partial Horizontal Laryngectomy as a Conservative Salvage Treatment for Laser-Recurrent Laryngeal Cancer: A Multi-Institutional Series
by
Erika Crosetti, Andrea Borello, Andy Bertolin, Izabela Costa Santos, Marco Fantini, Giulia Arrigoni, Ilaria Bertotto, Andrea Elio Sprio, Fernando Luiz Dias, Giuseppe Rizzotto and Giovanni Succo
Curr. Oncol. 2025, 32(1), 12; https://doi.org/10.3390/curroncol32010012 - 27 Dec 2024
Abstract
Early-stage laryngeal cancer (T1-T2) is commonly treated with organ-preserving techniques such as transoral laser microsurgery (TOLMS) or radiation therapy (RT), both providing comparable oncological outcomes but differing in functional results. Local recurrence occurs in approximately 10% of cases, making salvage surgery a crucial
[...] Read more.
Early-stage laryngeal cancer (T1-T2) is commonly treated with organ-preserving techniques such as transoral laser microsurgery (TOLMS) or radiation therapy (RT), both providing comparable oncological outcomes but differing in functional results. Local recurrence occurs in approximately 10% of cases, making salvage surgery a crucial therapeutic option. This multi-institutional study investigates the efficacy of open partial horizontal laryngectomy (OPHL) as a salvage treatment, following recurrent laryngeal squamous-cell carcinoma (LSCC) after failed TOLMS. This analysis includes 66 patients who underwent OPHL between 1995 and 2017, reporting favorable oncological outcomes with overall survival (OS) of 87.4%, disease-specific survival (DSS) of 93.4%, and disease-free survival (DFS) of 85.5%. A recurrence rate of 10.6% was observed post-salvage OPHL, with vascular invasion and advanced pathological staging identified as significant predictors of recurrence. OPHL emerged as an effective organ-preserving alternative to total laryngectomy (TL) in select patients, especially those with limited tumor spread and preserved laryngeal function. The study highlights the importance of careful patient selection and thorough preoperative assessment to improve outcomes, positioning OPHL as a key option in treating recurrent laryngeal cancer and offering oncological control while preserving laryngeal functions.
Full article
(This article belongs to the Special Issue The 30th Anniversary of Current Oncology: Perspectives in Clinical Oncology Practice)
►▼
Show Figures
Figure 1
Figure 1
Open AccessArticle
Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study
by
Ilya Tsimafeyeu, Vyacheslav Chubenko, Olga Baklanova, Alexey Kalpinskiy, Sufia Safina, Andrei Lebedinets, Vladislav Petkau, Elvira Parsadanova, Maria Turganova, Aleksei Shkurat, Natalia Tovbik, Elena Tkacheva, Yulia Anzhiganova, Olga Novikova, Varvara Bragina, Ruslan Zukov and Rashida Orlova
Curr. Oncol. 2025, 32(1), 11; https://doi.org/10.3390/curroncol32010011 - 27 Dec 2024
Abstract
Background: The RAVE-Renal study was conducted to evaluate the real-world efficacy and safety of avelumab plus axitinib as a first-line therapy for patients with metastatic renal cell carcinoma (mRCC). Methods: RAVE-Renal was a multicenter, noninterventional, ambispective study with both retrospective and prospective components.
[...] Read more.
Background: The RAVE-Renal study was conducted to evaluate the real-world efficacy and safety of avelumab plus axitinib as a first-line therapy for patients with metastatic renal cell carcinoma (mRCC). Methods: RAVE-Renal was a multicenter, noninterventional, ambispective study with both retrospective and prospective components. The study included adult patients with histologically confirmed mRCC, measurable disease per RECIST version 1.1, and no prior systemic therapy. Patients received avelumab (800 mg intravenously every 2 weeks) plus axitinib (5 mg orally twice daily). The primary endpoints were median progression-free survival (PFS) and objective response rate (ORR). The secondary endpoints included median OS, 1-year overall survival (OS) rate, and safety. Results: A total of 125 patients from 13 sites were enrolled, with a median follow-up of 16.1 months. The median age was 61.0 years. The study population comprised 35.3% favorable, 49% intermediate, and 15.7% poor IMDC risk patients. The median PFS was 14.9 months (95% CI, 11.72–19.08). The ORR was 44.3% (95% CI, 32.5–56.1). The clinical benefit rate was 93.4%. The 1-year OS rate was 71.2%, with the median OS not reached. Any-grade treatment-related adverse events (TRAEs) occurred in 99 (79.2%) cases, including grade ≥3 TRAEs in 24 (19.2%). Conclusions: Avelumab in combination with axitinib showed clinical benefits in a real-world setting, consistent with findings from a pivotal trial. The regimen was effective and well tolerated across various patient subgroups.
Full article
(This article belongs to the Special Issue Renal Cell Carcinoma Management)
►▼
Show Figures
Figure 1
Figure 1
Open AccessBrief Report
Matched Unrelated Donor Hematopoietic Cell Transplantation: Increased Usage and Improvements in Clinical Outcomes in Canada
by
Matthew D. Seftel, Grace Musto, David Allan, Oliver Bucher, Kevin Hay, Ivan Pasic, Tony Truong and Kristjan Paulson
Curr. Oncol. 2025, 32(1), 10; https://doi.org/10.3390/curroncol32010010 - 27 Dec 2024
Abstract
In allogeneic hematopoietic cell transplantation (HCT), a minority of patients have access to a suitable human leukocyte antigen (HLA)-matched related donor (MRD). To fill this gap, matched unrelated donors (MUDs) are an increasingly selected donor source. Usage and outcomes after MUD HCT for
[...] Read more.
In allogeneic hematopoietic cell transplantation (HCT), a minority of patients have access to a suitable human leukocyte antigen (HLA)-matched related donor (MRD). To fill this gap, matched unrelated donors (MUDs) are an increasingly selected donor source. Usage and outcomes after MUD HCT for Canada are not described. We investigated temporal trends in MUD compared to MRD HCT from 2000 to 2019 using data reported to the Cell Therapy and Transplant Canada (CTTC) Registry. Of 7571 first allogeneic HCTs between 2000 and 2019, the proportion of MUD HCTs rose from 35.1% to 56.3% in the early (2000–2009) and later (2010–2019) eras, respectively. Comparing the two donor sources, the 5-year overall survival (OS) after MUD HCT for patients with malignant diseases was inferior to MRD HCT in the early era (p < 0.001). However, in the later era, OS was comparable for the two donor sources (p = 0.969). For patients with non-malignant diseases, the 5-year OS after MUD HCT was inferior to MRD in the early era (p < 0.001), but in the later era, the 5-year OS was similar between the two donor sources (p = 0.209). Improvements in OS after MUD HCT were accompanied by corresponding reductions in the 2-year non-relapse mortality after MUD HCT. We conclude that MUDs are the most common donor source in Canada, and key clinical outcomes after MUD have improved over time.
Full article
(This article belongs to the Section Cell Therapy)
Open AccessArticle
Evaluating [68Ga]-Ga PSMA PET/CT for Detecting Prostate Cancer Recurrence Post-High-Intensity Focused Ultrasound and Brachytherapy: A Single-Center Retrospective Study
by
Andrea Di Giorgio, Marco Rapa, Simona Civollani, Andrea Farolfi and Stefano Fanti
Curr. Oncol. 2025, 32(1), 9; https://doi.org/10.3390/curroncol32010009 - 26 Dec 2024
Abstract
Focal therapy offers a promising approach for treating localized prostate cancer (PC) with minimal invasiveness and potential cost benefits. High-intensity focused ultrasound (HIFU) and brachytherapy (BT) are among these options but lack long-term efficacy data. Patient follow-ups typically use biopsies and multiparametric MRI
[...] Read more.
Focal therapy offers a promising approach for treating localized prostate cancer (PC) with minimal invasiveness and potential cost benefits. High-intensity focused ultrasound (HIFU) and brachytherapy (BT) are among these options but lack long-term efficacy data. Patient follow-ups typically use biopsies and multiparametric MRI (mpMRI), which often miss recurrences. PET/CT with PSMA has emerged as a promising tool for detecting residual disease or recurrence post-treatment, offering higher sensitivity and specificity than traditional imaging. We retrospectively reviewed patients who underwent [⁶⁸Ga]Ga-PSMA-11 PET/CT for biochemical recurrence (BCR) after HIFU or brachytherapy from 2016 to 2024. Out of 22 patients, 32% had HIFU and 68% had brachytherapy. The median time from treatment to PET scan was 77 months, with a median PSA level of 3 ng/mL. [[⁶⁸Ga]Ga-PSMA-11 PET/CT identified PC recurrence in 63.6% of cases. Of these, 50% showed prostate recurrence, 14% had lymph node involvement, and 28% had metastatic disease. Focal therapies like HIFU and brachytherapy are effective and minimally invasive options for localized PC. [⁶⁸Ga]Ga-PSMA-11 PET/CT is valuable for detecting recurrence or residual disease, enhancing post-treatment surveillance.
Full article
Open AccessReview
Optimal Pathways to Lung Cancer Screening in Primary Care Settings: A Scoping Review
by
Emmanouil K. Symvoulakis, Izolde Bouloukaki, Antonios Christodoulakis, Antonia Aravantinou-Karlatou and Ioanna Tsiligianni
Curr. Oncol. 2025, 32(1), 8; https://doi.org/10.3390/curroncol32010008 - 26 Dec 2024
Abstract
►▼
Show Figures
Lung cancer is the leading cause of cancer-related deaths worldwide, and delayed detection contributes to poor outcomes. Primary care plays a crucial role in early diagnosis, but detecting lung cancer early remains challenging for general practitioners (GPs). Therefore, the aim of this scoping
[...] Read more.
Lung cancer is the leading cause of cancer-related deaths worldwide, and delayed detection contributes to poor outcomes. Primary care plays a crucial role in early diagnosis, but detecting lung cancer early remains challenging for general practitioners (GPs). Therefore, the aim of this scoping review was to identify optimal strategies and pathways for lung cancer screening (LCS) in primary care settings globally. We conducted a scoping review by searching PubMed, Scopus, and the Cochrane Library for relevant studies published in the past 10 years. Our keywords included “lung cancer”, “primary care”, “early detection”, “screening”, “best practices”, and “pathways”. We included randomized controlled trials, cross-sectional studies, and cohort studies focused on lung cancer screening in primary care. We extracted data on study characteristics, screening pathways, and key findings. We identified 18 studies that met our inclusion criteria. Important strategies for LCS included the use of shared decision-making tools, electronic health record (HER) prompts, risk prediction models, community outreach, and integration with smoking cessation programs. Barriers to implementation included the lack of provider familiarity with guidelines, time constraints, and patient factors. Healthcare professionals and policy makers in primary care settings can leverage this information to integrate the most effective screening strategies into their care, thus enhancing early detection rates and subsequently reducing global lung cancer morbidity and mortality.
Full article
Graphical abstract
Graphical abstract
Open AccessArticle
AI-Enhanced Healthcare: Integrating ChatGPT-4 in ePROs for Improved Oncology Care and Decision-Making: A Pilot Evaluation
by
Chihying Liao, Chinnan Chu, Mingyu Lien, Yaochung Wu and Tihao Wang
Curr. Oncol. 2025, 32(1), 7; https://doi.org/10.3390/curroncol32010007 - 26 Dec 2024
Abstract
Background: Since 2023, ChatGPT-4 has been impactful across several sectors including healthcare, where it aids in medical information analysis and education. Electronic patient-reported outcomes (ePROs) play a crucial role in monitoring cancer patients’ post-treatment symptoms, enabling early interventions. However, managing the voluminous ePRO
[...] Read more.
Background: Since 2023, ChatGPT-4 has been impactful across several sectors including healthcare, where it aids in medical information analysis and education. Electronic patient-reported outcomes (ePROs) play a crucial role in monitoring cancer patients’ post-treatment symptoms, enabling early interventions. However, managing the voluminous ePRO data presents significant challenges. This study assesses the feasibility of utilizing ChatGPT-4 for analyzing side effect data from ePROs. Methods: Thirty cancer patients were consecutively collected via a web-based ePRO platform, reporting side effects over 4 weeks. ChatGPT-4, simulating oncologists, dietitians, and nurses, analyzed this data and offered improvement suggestions, which were then reviewed by professionals in those fields. Results: Two oncologists, two dieticians, and two nurses evaluated the AI’s performance across roles with 540 reviews. ChatGPT-4 excelled in data accuracy and completeness and was noted for its empathy and support, enhancing communication and reducing caregiver stress. It was potentially effective as a dietician. Discussion: This study offers preliminary insights into the feasibility of integrating AI tools like ChatGPT-4 into ePRO cancer care, highlighting its potential to reduce healthcare provider workload. Key directions for future research include enhancing AI’s capabilities in cancer care knowledge validation, emotional support, improving doctor-patient communication, increasing patient health literacy, and minimizing errors in AI-driven clinical processes. As technology advances, AI holds promise for playing a more significant role in ePRO cancer care and supporting shared decision-making between clinicians and patients.
Full article
(This article belongs to the Special Issue Feature Reviews in Section "Oncology Nursing")
►▼
Show Figures
Graphical abstract
Graphical abstract
Open AccessArticle
A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer
by
Danilo Giffoni de Mello Morais Mata, Rossanna C. Pezo, Kelvin K. W. Chan, Ines Menjak, Andrea Eisen and Maureen Trudeau
Curr. Oncol. 2025, 32(1), 6; https://doi.org/10.3390/curroncol32010006 - 25 Dec 2024
Abstract
Background: Anthracycline–taxane chemotherapy is the gold standard in high-risk breast cancer (BC), despite the potential risk of congestive heart failure (CHF). A suitable alternative for anthracycline-sparing chemotherapy is through the combination of docetaxel and cyclophosphamide (TC). Methods: Through a retrospective study of stage
[...] Read more.
Background: Anthracycline–taxane chemotherapy is the gold standard in high-risk breast cancer (BC), despite the potential risk of congestive heart failure (CHF). A suitable alternative for anthracycline-sparing chemotherapy is through the combination of docetaxel and cyclophosphamide (TC). Methods: Through a retrospective study of stage I-III HER2-negative BC, using administrative databases, we analyzed a total of 10,634 women treated with adjuvant chemotherapy in Ontario, Canada, between 2009 and 2017. We compared TC versus standardized anthracycline–taxane chemotherapies (ACT and FEC-D). We investigated the overall survival (OS), and explored the incidence of CHF, emergency department (ED) visits and febrile neutropenia. Results: With a median follow-up of 5.5 years, the 5-year analysis showed an increased OS in patients treated with TC, versus those treated with ACT, HR 0.77 (0.63–0.95, p = 0.015). Among ER+ BC, there was an increased OS in patients treated with ACT and FEC-D, versus those treated with TC, HR 0.70 (0.52–0.95, p = 0.021) and HR 0.71 (0.56–0.91, p = 0.007), respectively. There were no substantial differences in CHF, between TC and anthracycline-based treatments. Patients treated with TC and FEC-D had more ED visits, compared to those treated with ACT. Conclusion: Our study shows that anthracycline–taxane regimens were the most commonly prescribed adjuvant chemotherapy options in HER2-negative BC. Women who received ACT had the lowest OS, likely due to their unfavorable pathology.
Full article
(This article belongs to the Section Breast Cancer)
►▼
Show Figures
Figure 1
Figure 1
Open AccessArticle
Improving Cancer Diagnosis in Alberta, Canada: A Qualitative Study of Emergency Department Healthcare Providers’ Perspectives on Diagnosing Cancer in the Emergency Setting
by
Anna Pujadas Botey, Cassandra Carrier, Eddy Lang and Paula J. Robson
Curr. Oncol. 2025, 32(1), 5; https://doi.org/10.3390/curroncol32010005 - 25 Dec 2024
Abstract
►▼
Show Figures
Cancer is the leading cause of death in Canada, with diagnoses increasing annually. In Alberta, many cancer cases are detected in emergency departments, often at advanced stages. Despite the significant role of emergency departments in cancer diagnosis, limited research exists on the experiences
[...] Read more.
Cancer is the leading cause of death in Canada, with diagnoses increasing annually. In Alberta, many cancer cases are detected in emergency departments, often at advanced stages. Despite the significant role of emergency departments in cancer diagnosis, limited research exists on the experiences of healthcare providers in this context. This qualitative study aimed to explore the perspectives of physicians and nurses working in emergency departments in Edmonton and Calgary regarding cancer diagnosis. Semi-structured interviews were conducted with 17 physicians and nurses, recruited through convenience and snowball sampling. Data collection continued until thematic saturation was reached. Interviews were analyzed thematically using an inductive, iterative process. Three main themes emerged: the acute care focus of the emergency department, its unsuitability for cancer diagnosis, and the need for systemic improvements to better support patients with suspected cancer. Participants highlighted challenges related to high patient volumes, the emotional burden of delivering cancer diagnoses, and barriers to effective communication and patient interaction in a fast-paced, high-pressure environment. The findings suggest the need for systemic reforms, including stronger primary care and improved care coordination, to alleviate pressure on emergency departments and enhance both patient outcomes and healthcare provider well-being.
Full article
Graphical abstract
Open AccessCase Report
Vulvar Metastasis in Renal Cell Carcinoma: A Case Report Highlighting the Aggressive Nature of Clear Cell Renal Cell Carcinoma
by
Andreea Boiangiu, Ana-Maria Cioca, Gabriel-Petre Gorecki, Romina-Marina Sima, Liana Pleș, Marius-Bogdan Novac, Ionut-Simion Coman, Valentin-Titus Grigorean, Vasile Lungu, Mihai-Teodor Georgescu and George-Alexandru Filipescu
Curr. Oncol. 2025, 32(1), 4; https://doi.org/10.3390/curroncol32010004 - 25 Dec 2024
Abstract
►▼
Show Figures
Vulvar cancer is one of the rarest gynecological malignancies. The development of this condition can be associated with either dysplasia linked to human papillomavirus (HPV), primarily affecting younger women, or vulvar dermatoses such as lichen sclerosus, which predominantly affect older women. Over the
[...] Read more.
Vulvar cancer is one of the rarest gynecological malignancies. The development of this condition can be associated with either dysplasia linked to human papillomavirus (HPV), primarily affecting younger women, or vulvar dermatoses such as lichen sclerosus, which predominantly affect older women. Over the last decade, the incidence of vulvar cancer has risen by 0.6% annually, while the relative survival rate has declined. Although metastasis to the vulva is uncommon, it can occur, particularly from cancers in nearby organs such as the cervix, bladder, rectum, or anus. More rarely, metastases from breast cancer and renal cell carcinoma have been reported in the vulva. Vaginal metastases from clear cell renal carcinoma are especially rare. In this article, we present the case of a 56-year-old patient diagnosed with clear cell renal carcinoma, who came to our clinic with a lesion on the right labia, which was identified as a metastasis originating from the kidney. Given the rarity of genital metastases in renal cancer, such cases should be examined and discussed to encourage further research and studies.
Full article
Figure 1
Figure 1
Open AccessReview
Nutritional Counseling During Chemotherapy Treatment: A Systematic Review of Feasibility, Safety, and Efficacy
by
Shalet James, Alexie Oppermann, Kaitlin M. Schotz, Mackenzie M. Minotti, Gautam G. Rao, Ian R. Kleckner, Brenton J. Baguley and Amber S. Kleckner
Curr. Oncol. 2025, 32(1), 3; https://doi.org/10.3390/curroncol32010003 - 24 Dec 2024
Abstract
Dietary interventions during chemotherapy hold promise for clinical and supportive care outcomes. We systematically investigated the feasibility, safety, and efficacy of nutritional counseling conducted during chemotherapy. Studies prospectively implemented nutrition counseling during chemotherapy. Articles were identified from three databases—EMBASE, Cochrane Library, and SCOPUS—from
[...] Read more.
Dietary interventions during chemotherapy hold promise for clinical and supportive care outcomes. We systematically investigated the feasibility, safety, and efficacy of nutritional counseling conducted during chemotherapy. Studies prospectively implemented nutrition counseling during chemotherapy. Articles were identified from three databases—EMBASE, Cochrane Library, and SCOPUS—from inception to 1 October 2024. Feasibility, safety, and efficacy of outcome data were extracted. Among 44 publications, 39 studies recruited 98 ± 80 participants (range 15–360); 38/39 (97%) were randomized controlled trials. One-third (31%) were among patients with breast cancer. Interventions were divided into individualized nutritional counseling (n = 21), nutrition counseling plus exercise (n = 13), and nutrient-specific dietary patterns (n = 10). Many had goals to achieve established nutrition guidelines. Feasibility was high based on attendance at counseling sessions, retention, and/or food log analysis. Overall, there were minimal adverse events related to the interventions. Many studies showed between-group differences favoring the intervention group for body weight (8/24, gain or loss, according to goals), nutritional status (8/9), quality of life (3/10 without and 6/9 with exercise), cancer-related fatigue (7/10), chemotherapy tolerance (6/11), and treatment responses (3/13). In conclusion, nutritional interventions were feasible and safe for patients undergoing chemotherapy and demonstrated preliminary efficacy to improve nutritional status, fatigue, chemotherapy tolerance, and other outcomes.
Full article
(This article belongs to the Special Issue Diet and Physical Activity Management during Cancer)
►▼
Show Figures
Graphical abstract
Graphical abstract
Open AccessArticle
Real-World Characterization of Toxicities and Medication Management in Recipients of CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma in Nova Scotia, Canada
by
Jenna Shaw, Mahmoud Elsawy, Rachel Nielsen, Amye Michelle Harrigan, Tara T. DiCostanzo and Laura V. Minard
Curr. Oncol. 2025, 32(1), 2; https://doi.org/10.3390/curroncol32010002 - 24 Dec 2024
Abstract
►▼
Show Figures
Nova Scotia (NS) began offering CAR T-cell therapy as a third-line standard of care for eligible patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) in 2022. Recipients of CAR T-cell therapy often experience acute toxicities, including cytokine release syndrome (CRS) and
[...] Read more.
Nova Scotia (NS) began offering CAR T-cell therapy as a third-line standard of care for eligible patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) in 2022. Recipients of CAR T-cell therapy often experience acute toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which require close monitoring and prompt management. This retrospective review aimed to describe the characteristics of adult patients with r/r LBCL deemed eligible to receive CAR T-cell therapy with axicabtagene ciloleucel in NS between January 2022 and June 2024, the toxicities experienced and toxicity management, hospital visits and intensive care unit (ICU) admissions, the utilization of toxicity management guidelines, and general efficacy outcomes. Twenty-seven patients received axicabtagene ciloleucel. All patients experienced CRS (7.4% grade ≥ 3), and 55.6% developed ICANS (25.9% grade ≥ 3). The median hospital stay was 18 days, with 40.7% requiring ICU admission. There was one treatment-related mortality. Most CRS (85.2%) and ICANS (80.0%) cases were managed according to the guidelines. By day +100, the best objective response rate was 81.5% (44.4% complete responses). Patients who received CAR T-cell therapy in NS, Canada, experienced comparable toxicities and efficacy to those reported in pivotal clinical trials and other real-world experiences.
Full article
Figure 1
Figure 1
Open AccessArticle
The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre
by
Anna-Maria Lazaratos, Matthew Dankner, Aalya Hamouda, Soumaya Labidi, Victor Cohen, Lawrence Panasci, Jennifer E. Friedmann, François Patenaude, Cristiano Ferrario, Mark Basik, April A. N. Rose and Parvaneh Fallah
Curr. Oncol. 2025, 32(1), 1; https://doi.org/10.3390/curroncol32010001 - 24 Dec 2024
Abstract
►▼
Show Figures
Background: Trastuzumab deruxtecan (TDXd) is an antibody–drug conjugate that has demonstrated impressive activity in randomized controlled clinical trials in the context of patients with HER2-amplified and HER2-low metastatic breast cancer. We aimed to review the activity and adverse event profile of TDXd in
[...] Read more.
Background: Trastuzumab deruxtecan (TDXd) is an antibody–drug conjugate that has demonstrated impressive activity in randomized controlled clinical trials in the context of patients with HER2-amplified and HER2-low metastatic breast cancer. We aimed to review the activity and adverse event profile of TDXd in heavily pretreated breast cancer patients in real practice. Methods: We describe a single-center retrospective case series of metastatic breast cancer patients who were treated with TDXd. The outcomes of interest were the overall response rate, overall survival, progression-free survival and grade 4–5 adverse events. Objective responses and PFS were assessed in accordance with RECIST 1.1 criteria. Results: We identified 38 patients treated with TDXd. Of these, 15 patients had classically defined HER2-positive (HER2+) breast cancer, 4 of whom had active central nervous system (CNS) metastases. A total of 23 patients had HER2-low breast cancer, 2 of whom had active CNS disease. Of the 33 patients evaluable for response, 21 (63%) patients had a response to treatment, including three (9%) complete responses. Outcomes were similar between patients with a HER2+ and HER2-low status, as well as in patients with or without CNS metastases. No patients experienced grade 4 or 5 toxicities, and four of thirty-eight patients (10.5%) experienced pneumonitis (two patients with grade 3 pneumonitis, one patient with grade 2 and one patient with grade 1), resulting in TDXd discontinuation for three patients (with steroid administration in two patients). Conclusions: TDXd demonstrates impressive activity with manageable adverse event profiles in this heavily pretreated population that includes patients with active CNS metastases.
Full article
Figure 1
Figure 1
Open AccessCase Report
Metabolic Complete Response of Metastatic Oncogene-Negative, PDL1-Negative Non-Small Cell Lung Cancer After Chemo-Immunotherapy and Radiotherapy: A Case Report
by
Alessia Surgo, Valerio Davì, Maria Paola Ciliberti, Roberta Carbonara, Morena Caliandro, Fiorella Cristina Di Guglielmo, Nicola Sasso, Roberto Calbi, Maria Annunziata Gentile, Tiziana Talienti, Isabella Bruno, Michele Troia, Ilaria Bonaparte, Giuseppe Mario Ludovico, Giammarco Surico and Alba Fiorentino
Curr. Oncol. 2024, 31(12), 8118-8126; https://doi.org/10.3390/curroncol31120598 - 23 Dec 2024
Abstract
A 71-year-old male ex-smoker presented in October 2021 to our department with a brain and bone metastatic adenocarcinoma NSCLC. PDL1, ROS, EGFR, and ALK were negative. He underwent stereotactic radiotherapy for brain metastases. In November 2021, he started a chemotherapy (CHT) regimen with
[...] Read more.
A 71-year-old male ex-smoker presented in October 2021 to our department with a brain and bone metastatic adenocarcinoma NSCLC. PDL1, ROS, EGFR, and ALK were negative. He underwent stereotactic radiotherapy for brain metastases. In November 2021, he started a chemotherapy (CHT) regimen with cisplatin (75 mg/m2 every 21 days) and pemetrexed (500 mg/m2 every 21 days), and ICI with Atezolizumab (1200 mg every 21 days). In July 2022, RT to the lung tumor and mediastinal nodal was performed with a total dose of 45 Gy in 15 fractions. He continued with immunotherapy until December 2022, when a grade 3–4 toxicity from immunotherapy was observed (hypothyroidism, psoriasis, and cystitis). He achieved a complete clinical response to the therapy. To date, the patient is alive, with a complete metabolic response, without treatment at 37 months from diagnosis.
Full article
(This article belongs to the Special Issue New Challenges and Advances in the Treatment of Lung Cancer: From Predictive Biomarkers to Minimally Invasive Techniques)
►▼
Show Figures
Figure 1
Figure 1
Open AccessArticle
Rural Versus Urban Genitourinary Cancer Incidence and Mortality in Pennsylvania: 1990–2019
by
Jonathan Pham, Ahmad N. Alzubaidi, Jay D. Raman and Tullika Garg
Curr. Oncol. 2024, 31(12), 8110-8117; https://doi.org/10.3390/curroncol31120597 - 23 Dec 2024
Abstract
Our aim was to describe the incidence and mortality of genitourinary (GU) cancers in rural and urban Pennsylvania counties. We calculated age-adjusted incidence and mortality rates of GU (prostate, bladder, and kidney) cancers from 1990 to 2019 in the Pennsylvania Cancer Registry. We
[...] Read more.
Our aim was to describe the incidence and mortality of genitourinary (GU) cancers in rural and urban Pennsylvania counties. We calculated age-adjusted incidence and mortality rates of GU (prostate, bladder, and kidney) cancers from 1990 to 2019 in the Pennsylvania Cancer Registry. We defined rurality using the Center for Rural Pennsylvania’s population density-based definition. We modeled average annual percent changes (AAPC) in age-adjusted incidence and mortality rates using joinpoint regression. Overall GU cancer incidence decreased in rural and urban counties (AAPC −7.5%, p = 0.04 and AAPC −6.6%, p = 0.02, respectively). Prostate cancer incidence decreased in rural and urban counties by −10.5% (p = 0.02) and −9.1% (p = 0.01), respectively. Kidney cancer incidence increased in both rural and urban counties, respectively (AAPC = +11.2, p = 0.002 and +9.3%, p = 0.01). GU cancer mortality decreased in rural and urban counties (AAPC = −11.6, p = 0.047 and AAPC −12.2, p = 0.01, respectively). Prostate cancer mortality decreased at similar rates in rural and urban counties (AAPC −15.5, p = 0.03 and −15.4, p = 0.02, respectively). Kidney cancer mortality decreased in urban (AAPC −6.9% p = 0.03) but remained stable in rural counties. Bladder cancer incidence and mortality were unchanged in both types of counties. Over three decades, GU cancer incidence and mortality decreased across Pennsylvania counties.
Full article
(This article belongs to the Section Genitourinary Oncology)
►▼
Show Figures
Figure 1
Figure 1
Open AccessReview
Let It Grow: The Role of Growth Factors in Managing Chemotherapy-Induced Cytopenia
by
Ruah Alyamany, Ahmed Alnughmush, Hazzaa Alzahrani and Mansour Alfayez
Curr. Oncol. 2024, 31(12), 8094-8109; https://doi.org/10.3390/curroncol31120596 - 21 Dec 2024
Abstract
Chemotherapy-induced cytopenia (CIC) is characterized by neutropenia, anemia, and thrombocytopenia, which are common and serious complications in cancer treatment. These conditions affect approximately 60% of patients undergoing chemotherapy and can significantly impact quality of life, treatment continuity, and overall survival. The use of
[...] Read more.
Chemotherapy-induced cytopenia (CIC) is characterized by neutropenia, anemia, and thrombocytopenia, which are common and serious complications in cancer treatment. These conditions affect approximately 60% of patients undergoing chemotherapy and can significantly impact quality of life, treatment continuity, and overall survival. The use of growth factors, including granulocyte colony-stimulating factors (GCSFs), erythropoietin-stimulating agents (ESAs), and thrombopoietin receptor agonists (TPO-RAs), has emerged as a promising strategy for managing CIC. However, the use of these growth factors must be approached with caution. This review provides an overview of the mechanisms, efficacy, and safety of growth factors in the management of CIC. Additionally, we discuss predictive markers for treatment response, potential risks, and highlight areas for future research.
Full article
Journal Menu
► ▼ Journal Menu-
- Current Oncology Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Topical Advisory Panel
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Society Collaborations
- Editorial Office
- 30th Anniversary
Journal Browser
► ▼ Journal Browser-
arrow_forward_ios
Forthcoming issue
arrow_forward_ios Current issue - Volumes not published by MDPI
Highly Accessed Articles
Latest Books
E-Mail Alert
News
Topics
Topic in
Cancers, Diagnostics, JCM, Pharmaceutics, Current Oncology
From Basic Research to a Clinical Perspective in Oncology
Topic Editors: Bianca Gǎlǎţeanu, Octav Ginghină, Ariana HuditaDeadline: 31 December 2024
Topic in
Biomedicines, Cancers, Current Oncology, Onco, Pathophysiology
Individualized Molecular Mechanisms and Treatment in Tumor Metastasis
Topic Editors: Dong Tang, Chen Liu, Bin ChengDeadline: 5 January 2025
Topic in
Cancers, Cells, JCM, Radiation, Pharmaceutics, Applied Sciences, Nanomaterials, Current Oncology
Innovative Radiation Therapies
Topic Editors: Gérard Baldacchino, Eric Deutsch, Marie Dutreix, Sandrine Lacombe, Erika Porcel, Charlotte Robert, Emmanuelle Bourneuf, João Santos Sousa, Aurélien de la LandeDeadline: 30 April 2025
Topic in
Biomedicines, Current Oncology, Diagnostics, Gastrointestinal Disorders, JCM
Advances in Gastrointestinal and Liver Disease: From Physiological Mechanisms to Clinical Practice
Topic Editors: Davide Giuseppe Ribaldone, Gian Paolo CavigliaDeadline: 20 June 2025
Conferences
Special Issues
Special Issue in
Current Oncology
Advancements in Clinical Trials in Oncology: Design, Enrichment, Safety, Operations, Patient Centricity, and Endpoints
Guest Editor: Brandon Michael HenryDeadline: 31 December 2024
Special Issue in
Current Oncology
2023–2024 Article Series of the Canadian Association of General Practitioners in Oncology
Guest Editor: Genevieve ChaputDeadline: 31 December 2024
Special Issue in
Current Oncology
Biliary Tract Cancer Updates: Advancements and Insights
Guest Editor: Kristen R. SpencerDeadline: 31 December 2024
Special Issue in
Current Oncology
An In-Depth Review of Desmoid Tumours
Guest Editor: Lloyd MackDeadline: 31 December 2024
Topical Collections
Topical Collection in
Current Oncology
New Insights into Prostate Cancer Diagnosis and Treatment
Collection Editor: Sazan Rasul
Topical Collection in
Current Oncology
New Insights into Breast Cancer Diagnosis and Treatment
Collection Editors: Filippo Pesapane, Matteo Suter
Topical Collection in
Current Oncology
Editorial Board Members’ Collection Series in "Exercise and Cancer Management"
Collection Editors: Linda Denehy, Ravi Mehrotra, Nicole Culos-Reed
Topical Collection in
Current Oncology
Editorial Board Members’ Collection Series: Contemporary Perioperative Concepts in Cancer Surgery
Collection Editors: Vijaya Gottumukkala, Jörg Kleeff